behenyl alcohol

(redirected from Docosanol)
Also found in: Medical, Wikipedia.

behenyl alcohol

[bə′hen·əl ′al·kə‚hȯl]
(organic chemistry)
CH3(CH2)20CH2OH A saturated fatty alcohol; colorless, waxy solid with a melting point of 71°C; soluble in ethanol and chloroform; used for synthetic fibers and lubricants. Also known as 1-docosanol.
Mentioned in ?
References in periodicals archive ?
In a multicenter, randomized, doubleblind study, patients who had experienced herpes simplex labialis (HSL) symptoms for 12 hours or less were given either docosanol cream (370 patients) or placebo (367 patients) to be applied to the lesion area five times per day until healed or for a maximum of 10 days (J.
Docosanol patients had a median healing time of just over 4 days, compared with almost 5 days for the controls.
We intend to extend our docosanol franchise throughout the world and expect to hear from the Medical Products Agency (MPA) in Sweden regarding potential approval within the current quarter.
AVANIR has extended its docosanol franchise by licensing docosanol to companies intending to market the product in certain countries in Europe, Asia and the Middle-East.
Abreva is the brand name in North America for docosanol 10% cream, a topical pharmaceutical approved for the treatment of cold sores.
We continued to expand our docosanol franchise, made significant progress in our clinical development of Neurodex, achieved advances in several preclinical programs, and added to the foundation of our Xenerex antibody technology.
Completing the Neurodex pivotal Phase III clinical trial for the treatment of PBA in MS patients, and the Phase II trial for the treatment of neuropathic pain; -- Initiating a Phase I clinical trial for our lead anti-IgE compound, a potential treatment for allergy and asthma; -- Advancing our docosanol franchise in other major markets, including additional international marketing licenses and regulatory filings in Europe and Asia; and -- Continuing Xenerex's research in antibody generation.
AVANIR's revenue grew over 1800 percent during this period in conjunction with FDA approval of the Company's lead product, docosanol 10% cream, and the subsequent launch of the product as Abreva(TM) in the U.
AVANIR intends to use the grant award to fund research for the development and testing of efficacy and safety in animal models of a new topical formulation of docosanol that could be used to treat genital herpes.
It is very important to us to have received this grant to continue development of docosanol for genital herpes," said AVANIR President and Chief Executive Officer Gerald J.